Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 608 participants.

Also called NCT04817215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 608 participants (planned count) (from the registry)
Sponsor
  • Oramed, Ltd. Registry lists this organization as a collaborator
Registry
  • NCT NCT04817215
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04817215. Randomized; double masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2022-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
ORMD-0801
Lead sponsor
King Hamad University Hospital, Bahrain (class: other)
Collaborator
Royal College of Surgeons in Ireland - Medical University of Bahrain (class: other)
Collaborator
Oramed, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04817215
Content hash
66f9869274edc22a2af03dc346835be6401d7859cf27f2685364c88a10d7f1ce